surpass 2 tirzepatide Read now: The SURPASS-EARLY trial found that starting #tirzepatide early in #type2diabetes led to greater improvements in blood sugar, body weight, and waist size than intensified standard care. https://bit.ly/3RWnB8m Overview of the SURPASS clinical

You see in Canada tirzepatide is formally approved for use in type 2 diabetes, however physicians regularly prescribe it off label (meaning for a condition it is not yet formally indicated by regulators) for use with obesity while we wait for Health Canada approval (the FDA approved it for obesity on November 8th, 2023, while the EUs European Commission approved it for obesity on April 24th, 2024)

On the contrast, carnitine supplementation (200 mg/kg/day) for 28 successive days showed non-significant changes

Sermorelin (HGH Releaser): Peptide used to boost natural growth hormone, increasing lean muscle mass and targeting fat reduction

Extracellular aggregated Cu/Zn superoxide dismutase activates microglia to give a cytotoxic phenotype